Intech Biopharm Corporation (TPEX:6461)

Intech Biopharm Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	95.42	16.8	198.65	77.73	64.82	220.48
Short-Term Investments	50	197.5	60	520	310	115
Cash & Short-Term Investments	145.42	214.3	258.65	597.73	374.82	335.48
Cash Growth	-73.25%	-17.15%	-56.73%	59.47%	11.73%	10.11%
Accounts Receivable	7.85	4.38	9.28	3.05	3.67	15.04
Other Receivables	3.16	2.59	9.83	8.7	7.94	7.94
Receivables	11.01	6.97	19.11	11.74	11.6	22.98
Inventory	137.26	116.48	63.86	41.53	51.82	59.87
Prepaid Expenses	76.74	65.38	68.65	43.62	40.7	33.74
Other Current Assets	0.14	-	0.06	0.41	0.13	4.26
Total Current Assets	370.57	403.13	410.32	695.02	479.06	456.33
Property, Plant & Equipment	1,381	1,403	1,885	1,900	2,009	2,090
Other Intangible Assets	5.18	4.89	3.86	4.88	4.8	4.62
Long-Term Deferred Tax Assets	24.77	24.77	24.77	24.77	24.77	24.77
Other Long-Term Assets	514.21	514.69	71.69	86.15	33.17	26.26
Total Assets	2,295	2,351	2,396	2,711	2,551	2,602

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	4.87	3.9	9.82	0.31	1.33	2.4
Accrued Expenses	-	26.44	28.82	19.24	23.71	20.82
Short-Term Debt	80	-	-	-	-	-
Current Portion of Long-Term Debt	-	192.73	248.82	464.65	265.26	211.66
Current Portion of Leases	0.4	0.39	-	-	-	-
Current Unearned Revenue	12.82	12.94	81.18	78.54	78.31	78.99
Other Current Liabilities	130.59	6.92	18	5.99	5.23	9.35
Total Current Liabilities	228.67	243.32	386.64	568.73	373.82	323.22
Long-Term Debt	1,154	994.9	1,188	970.41	1,143	940.77
Long-Term Leases	0.41	0.6	-	-	-	-
Long-Term Unearned Revenue	15.14	8.84	5.53	2.35	-	-
Pension & Post-Retirement Benefits	-	0.85	-	-	-	-
Long-Term Deferred Tax Liabilities	0.02	0.02	-	-	-	-
Other Long-Term Liabilities	3.13	1.45	1.72	1.74	1.54	-
Total Liabilities	1,401	1,250	1,582	1,543	1,519	1,264

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	1,784	1,784	1,379	1,374	1,170	1,163
Additional Paid-In Capital	6.16	282.09	19.76	286.16	195.15	481.32
Retained Earnings	-214.56	-959.57	-579.76	-488.08	-327.88	-301.76
Comprehensive Income & Other	-680.72	-5.58	-5.16	-4.32	-5.13	-4.72
Shareholders' Equity	894.4	1,101	814.28	1,168	1,032	1,338
Total Liabilities & Equity	2,295	2,351	2,396	2,711	2,551	2,602

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	1,235	1,189	1,436	1,435	1,409	1,152
Net Cash (Debt)	-1,089	-974.31	-1,178	-837.33	-1,034	-816.94
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-6.42	-6.42	-8.58	-6.95	-8.90	-8.03
Filing Date Shares Outstanding	174.08	178.41	137.94	137.41	116.96	116.28
Total Common Shares Outstanding	174.08	178.41	137.94	137.41	116.96	116.28
Working Capital	141.9	159.81	23.68	126.3	105.24	133.11
Book Value Per Share	5.14	6.17	5.90	8.50	8.82	11.50
Tangible Book Value	889.22	1,096	810.42	1,163	1,027	1,333
Tangible Book Value Per Share	5.11	6.14	5.87	8.46	8.78	11.46
Land	-	516.45	919.87	919.87	950.72	950.72
Buildings	-	756.97	791.07	790.24	798.32	810.2
Machinery	-	754.83	724.87	657.12	645.9	633.52

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 15, 2026

Data Sources Report a data error